The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Novel agents targeting the B-cell receptor pathway and BCL-2 have transformed chronic lymphocytic leukemia (CLL) treatment.
• Ibrutinib is a key targeted therapy in CLL management.

Purpose of the Study:

• To evaluate the real-world safety and efficacy of single-agent ibrutinib in patients with relapsed/refractory (R/R) CLL.
• To assess treatment outcomes and adverse events in a diverse patient cohort.

Main Methods:

• Retrospective, multicenter, non-interventional study of 200 R/R CLL patients.
• Data collected from patient charts, including demographics, treatment history, and outcomes.

Main Results:

• 75% of patients achieved at least partial response (PR) to ibrutinib.
• Most common adverse events included neutropenia, thrombocytopenia, and pneumonia.
• Median overall survival (OS) was 52 months, with response significantly correlating with OS.

Conclusions:

• Single-agent ibrutinib demonstrates favorable safety and efficacy in R/R CLL in daily clinical practice.
• Real-world data support the use of ibrutinib for R/R CLL patients.